Serina Therapeutics Announces Filing of Investigational New Drug (IND) Application for SER-214 for the Treatment of Parkinson’s Disease

Huntsville, AL, July 1, 2015

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a patented, proprietary polymer technology known as POZ, announced today that it has filed its first investigational new drug (IND) application with the Food and Drug Administration. The IND focuses on the Phase I development of SER-214, a once-per-week subcutaneous injectable for the treatment of Parkinson’s disease.

“The filing of the company’s first IND is a major milestone in the advancement of our polymer technology to develop POZ-therapeutics,” stated Randall Moreadith, MD, PhD, President and CEO of Serina Therapeutics. “With this milestone, and the recent announcement of a follow-on agreement with AstraZeneca, we are poised to introduce the first in a new series of polymer therapeutics into the clinic in 2015 and 2016.”

SER-214 is a POZ-conjugate that has the potent dopamine agonist rotigotine attached to the polymer backbone. In experimental animal studies in robust models of Parkinsonism SER-214 was shown to provide continuous drug delivery with a single weekly sc injection, and to rescue the motor fluctuations characteristic of Parkinson’s disease. The Phase Ia study is a multiple, ascending dose-ranging study that will be conducted in the USA at approximately 3-5 sites, with plans to begin patient recruitment in Q4-2015.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners. We believe our POZ technology provides strong differential characteristics that may demonstrate improved clinical benefits versus other polymer-based technologies. Besides developing its own pipeline of pharmaceutical products for Parkinson’s disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet medical needs.

Serina’s pipeline programs are aimed primarily at oncology indications that address significant unmet medical needs. Polymers of POZ can be targeted to specific receptors on the surface of cancer cells using either small molecules or antibodies (POZ polymer ADCs), and this approach may provide a much wider therapeutic index when employing very potent toxins attached to the polymer.

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com